AAN/AES Guidelines

Definitions^1,2

	Class I is defined as a prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population. The following are required: a) defined primary outcome(s) is/are clearly defined; b) exclusion/inclusion criteria are clearly defined; c) adequate accounting for dropouts and crossovers with numbers sufficiently low to have minimal potential for bias; d) relevant baseline characteristics are presented and are substantially equivalent among treatment groups, or there is appropriate statistical adjustment for differences
	Level A rating requires at least 1 convincing class I study or at least 2 consistent, convincing class II studies
	Level B rating requires at least 1 convincing class II study or at least 3 consistent class III studies
	Level C rating requires at least 2 convincing and consistent class III studies
	Level U means that the data were inadequate or conflicting; given the current knowledge, treatment is unproven

Learn about the efficacy of TRILEPTAL monotherapy

1.		French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology. 2004;62:1252-1260.
2.		French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology. 2004;62:1261-1273.